Staging ::: VER CORREOS
España
Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
13.573 / 17.039
#108580

Re: Farmas USA

Si me gusta mucho  la GILD... en esa me meti como los burricos hoy  pa dentro... aunque tengo la sensacion de que me apresure... mañana tendremos una corrección, abriremos por debajo del nivle del MM, y de ahi pa bajo... se q mañana o el viernes hubiese podido comprar a mejor precio estas Gild...pero no importa...la espero sobre los 76 pavos... y promdiare si cae ... a saber

 GILD

#108583

Re: Farmas USA

Top 25
anaramos

ADXS

Elimination of About 24% of Company’s Workforce as Part of Restructuring

new prioritization of its product portfolio

Advaxis has decided to reduce internal investment in axalimogene filolisbac (AXAL) and will seek partnership opportunities for AXAL in most human papillomavirus (HPV)-associated cancers, including cervical cancer. If the company is unable to secure a partner within a limited period of time, Advaxis will wind down the ongoing AIM2CERV trial in high-risk locally advanced cervical cancer, and will not conduct the ADVANCE PD-1 combination trial in metastatic cervical cancer, which has not yet been initiated. Advaxis has determined to focus future development efforts for AXAL on HPV-positive head-and-neck cancer through cost-effective clinical studies that are currently being explored.

ADXS-PSA combination trial with KEYTRUDA® on June 2nd at ASCO 2018. These data, while early, have proven worthy of further evaluation and the company will continue to follow patients for the next six to nine months in order to determine the path forward.

Advaxis has also decided to increase internal investment in the ADXS-NEO and ADXS-HOT programs, both of which target neoantigens, a potentially transformational, next-generation approach to treating cancer.

Advaxis expects that its annual cash burn will be approximately $50 million, down 38% from its prior annual cash burn of approximately $80 million.

As of April 30, 2018, the company had $58.8 million in cash, restricted cash, cash equivalents and short-term investment securities on its balance sheet.  the company has announced a workforce reduction effective June 7, 2018, and is in the process of making further cost-reduction decisions regarding select ongoing clinical trials.

...

https://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Reports+Elimination+of+About+24%25+of+Company%E2%80%99s+Workforce+as+Part+of+Restructuring/14283686.html

«Después de nada, o después de todo/ supe que todo no era más que nada.»